Advertisement

Drugs & Therapy Perspectives

, Volume 8, Issue 9, pp 12–16 | Cite as

What scope is there for improving the cost effectiveness of NSAIDs?

Drug Economics and Quality of Life
  • 6 Downloads

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bloor K, Maynard A. Is there scope for improving the cost-effective prescribing of nonsteroidal anti-inflammatory drugs? PharmacoEconomics 1996; 9(6): 484–96PubMedCrossRefGoogle Scholar
  2. 2.
    Wynne HA, Campbell M. Pharmacoeconomics of nonsteroidal anti-inflammatory drugs (NSAIDs). PharmacoEconomics 1994; 3(2): 107–23CrossRefGoogle Scholar
  3. 3.
    British National Formulary. No. 31. London: The Pharmaceutical Press. 1996 Mar: 403–12Google Scholar
  4. 4.
    Office of Health Economics. Arthritis. London: Office of Health Economics, 1992Google Scholar
  5. 5.
    Committee on the Safety of Medicines (CSM). Relative safety of oral non-aspirin NSAIDs: current problems in pharmacovigilence. London: CSM/Medicines Control Agency, 1994: 20Google Scholar
  6. 6.
    Maiden N, Madhok R. Misoprostol in patients taking non-steroidal anti-inflammatory drugs: best reserved for elderly patients at high risk. BMJ 1995; 311: 1518–9PubMedCrossRefGoogle Scholar
  7. 7.
    Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomised, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 241–9PubMedGoogle Scholar

Copyright information

© Adis International Limited 1996

Personalised recommendations